Utilisation des biomarqueurs du LCR dans le diagnostic de la maladie d'Alzheimer en pratique clinique

Taken together, in the current state of knowledge, use of CSF biomarkers in clinical practice should first be recommended for the assessment of early-onset cognitive disturbances, in particular when initial symptoms are of a non-memory type. Their development, however, offers new avenues in the fields of clinical and pharmacological research.